Clinical trial
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00016939 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00016939 |
|---|---|
| Title | Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer |
| Official title | A Phase II Study of Flavopiridol 1 Hour Bolus Days 1-3 Q 21 Days in Patients With Advanced Renal Cell Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | alvocidib |
| Start date | May 1, 2001 |
| Completion | Apr 1, 2006 |
| First posted | Sep 9, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: